Revenue growth is strong from new oncology contracts, but the rising medical expense ratio (93.0% vs 85.0%) and declining Adjusted EBITDA margin signal cost pressure. The raised EBITDA guidance suggests management expects margin improvement in Q4. Monitor the MER trajectory and cash flow conversion in the next quarter.
Price Chart
Executive Summary
Evolent Health reported Q3 2026 revenue of $725.4M, up 51% YoY, and a GAAP net loss of $23.6M, narrower than the $26.9M loss a year ago. The company reiterated its 2026 revenue guidance of $2.6B-$2.7B and raised its Adjusted EBITDA guidance to $130M-$135M, signaling improved profitability expectations.
Key Financial Metrics
Key Facts
- Q3 2026 revenue of $725.4M, up 51% from $479.5M in Q3 2025
- GAAP net loss of $23.6M vs $26.9M loss in Q3 2025
- Adjusted EBITDA of $34.3M vs $39.0M in Q3 2025; margin 4.7% vs 8.1%
- Medical Expense Ratio (MER) worsened to 93.0% from 85.0% a year ago
- Performance Suite revenue grew to $564.3M from $286.9M, driven by oncology launches
- Full year 2026 revenue guidance reiterated at $2.6B-$2.7B
- Full year 2026 Adjusted EBITDA guidance raised to $130M-$135M from $120M-$135M
- Cash and cash equivalents of $148.3M as of September 30, 2026
Financial Impact
Revenue grew 51% YoY to $725.4M; Adjusted EBITDA margin compressed to 4.7% from 8.1%; MER rose to 93.0% from 85.0%
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Performance Suite | $564.3M | +96.7% |
| Specialty Technology and Services Suite | $72.8M | -21.9% |
| Administrative Services | $48.3M | -16.5% |
| Cases | $40.0M | -3.8% |
Risk Factors
- Medical Expense Ratio increased to 93.0% from 85.0%, indicating higher claims costs
- Adjusted EBITDA margin declined to 4.7% from 8.1% despite revenue growth
- Net loss continues, though narrowed year-over-year
- High leverage with $969.5M in long-term debt against $372.9M in equity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628908-26-000102 |
| Document: evh-20261105.htm | 0001628908-26-000102 |
| Document: 0001628908-26-000102-index-headers.html | 0001628908-26-000102 |
| Document: 0001628908-26-000102-index.html | 0001628908-26-000102 |
| Document: 0001628908-26-000102.txt | 0001628908-26-000102 |
| 8-K Data (Synthetic) | 0001628908-26-000102 |
Track record
8 reports on EVH
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $4.82 Now $4.83 −0.31% settles Dec 15
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $4.74 Now $4.83 −1.90% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $4.54 Now $4.83 +6.39% settles Dec 4
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $3.59 to $4.26 Now $4.83 +34.54% ▲ +18.66% +18.06% vs SPY
- Jul 8, 202618w ago Press Release Neutral 1/10 Entry $5.63 to $3.59 Now $4.83 −14.21% ▼ −36.23% −38.48% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 2/10 Entry $3.47 to $3.83 Now $4.83 +39.19% ▲ +10.37% +5.42% vs SPY
- Feb 24, 202637w ago 8-K Mixed 6/10 Entry $3.14 to $2.27 Now $4.83 +53.82% ▼ −27.71% −22.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers